Hitomi Yamagami
Overview
Explore the profile of Hitomi Yamagami including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
62
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ito N, Kubota T, Kitanaka S, Fujiwara I, Adachi M, Takeuchi Y, et al.
J Bone Miner Metab
. 2021 Jul;
39(6):1066-1075.
PMID: 34255195
Introduction: Measurement of fibroblast growth factor 23 (FGF23) has been reported to be clinically useful for the differential diagnosis of chronic hypophosphatemia. However, assays for research use only are available...
2.
Shiiba M, Yamagami H, Sudo T, Tomokuni Y, Kashiwabara D, Kirita T, et al.
Heliyon
. 2020 Aug;
6(8):e04601.
PMID: 32793829
S-1 is an anticancer agent that is comprised of tegafur, gimeracil, and oteracil potassium, and is widely used in various carcinomas including oral squamous cell carcinoma (OSCC). Although an established...
3.
Yamagami H, Tanaka A, Kishino Y, Mikuni H, Kawahara T, Ohta S, et al.
Int J Chron Obstruct Pulmon Dis
. 2018 Jan;
13:79-89.
PMID: 29317813
Background: It is well known that increased airflow limitation as measured by spirometry is associated with the risk of exacerbation in patients with COPD. The forced oscillation technique (FOT) is...
4.
Shiiba M, Yamagami H, Yamamoto A, Minakawa Y, Okamoto A, Kasamatsu A, et al.
Oncol Rep
. 2017 Mar;
37(4):2025-2032.
PMID: 28259989
Resistance to anticancer medications often leads to poor outcomes. The present study explored an effective approach for enhancing chemotherapy targeted against human cancer cells. Real-time quantitative real-time polymerase chain reaction...
5.
Shiiba M, Saito K, Yamagami H, Nakashima D, Higo M, Kasamatsu A, et al.
Int J Oncol
. 2015 Mar;
46(5):1978-84.
PMID: 25738940
Inflammatory abnormalities have been implicated in the pathogenesis of various human diseases, including cancer. Interleukin-1 receptor antagonist (IL1RN) is a potent anti-inflammatory molecule that modulates the biological activity of the...